Options for induction immunosuppression in liver transplant recipients

被引:22
作者
Moser, MAJ [1 ]
机构
[1] London Hlth Sci Ctr, Ctr Multiorgan Transplant, London, ON N6A 5A5, Canada
关键词
D O I
10.2165/00003495-200262070-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immunosuppression administered in the early postoperative period following liver transplantation plays a crucial role in the survival of the graft and the patient. The introduction of cyclosporin was an important landmark in transplantation, and to this day, calcineurin inhibitors form the basis of most induction immunosuppression regimens. New drugs are being developed which are more specifically targeted to prevention of rejection, and multiple drug combinations have been proposed as a means of reducing the adverse effects of individual drugs. Azathioprine and the newer antimetabolite mycophenolate mofetil have been added to calcineurin inhibitor-based regimens with varying amounts of success. Antibody induction has evolved as a potent form of immunosuppression as well as a means of avoiding certain adverse effects, particularly nephrotoxicity. The numerous adverse effects encountered with polyclonal. preparations have been reduced with the development of more specific monoclonal antibodies such as muromonab CD3 (OKT3) or interleukin (IL)-2 receptor (IL-2R) antagonists. The anti-IL-2R antibody preparations basiliximab and daclizumab have shown excellent early results due to their potent yet highly targeted immuno suppressive effect and minimal adverse effects. Further study is needed to determine the most appropriate dosage, timing and patient population for these new drugs in the setting of liver transplantation. Although a number of different induction regimens have been described, no single protocol is suitable for all liver transplant recipients. Rather, certain regimens have advantages that could favour their use in a specific subgroup of patients. A number of clinical trials are underway to identify new, more specific drugs and combinations which could be useful in induction immunosuppression.
引用
收藏
页码:995 / 1011
页数:17
相关论文
共 75 条
[1]   An analysis of late deaths after liver transplantation [J].
Asfar, S ;
Metrakos, P ;
Fryer, J ;
Verran, D ;
Ghent, C ;
Grant, D ;
Bloch, M ;
Burns, P ;
Wall, W .
TRANSPLANTATION, 1996, 61 (09) :1377-1381
[2]   Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation [J].
Boillot, O ;
Baulieux, J ;
Wolf, P ;
Messner, M ;
Cherqui, D ;
Gugenheim, J ;
Pageaux, G ;
Belghiti, J ;
Calmus, Y ;
Le Treut, Y ;
Neau-Cransac, M ;
Samuel, D .
CLINICAL TRANSPLANTATION, 2001, 15 (03) :159-166
[3]  
BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110
[4]   Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients [J].
Calmus, Y ;
Scheele, JR ;
Gonzalez-Pinto, I ;
Jaurrieta, EJ ;
Klar, E ;
Pageaux, GP ;
Scudamore, CH ;
Cuervas-Mons, V ;
Metselaar, HJ ;
Prestele, H ;
Girault, D .
LIVER TRANSPLANTATION, 2002, 8 (02) :123-131
[5]  
Charlton M, 1999, LIVER TRANSPLANT SUR, V5, pS107
[6]   FUTURE OF MONOCLONAL-ANTIBODIES IN SOLID-ORGAN TRANSPLANTATION [J].
COSIMI, AB .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (01) :65-72
[7]  
COSIMI AB, 1990, ARCH SURG-CHICAGO, V125, P781
[8]  
Devlin J, 1996, TRANSPLANTATION, V62, P1251
[9]  
Eckhoff DE, 1998, TRANSPLANTATION, V65, P180
[10]   The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients [J].
Eckhoff, DE ;
McGuire, B ;
Sellers, M ;
Contreras, J ;
Frenette, L ;
Young, C ;
Hudson, S ;
Bynon, JS .
TRANSPLANTATION, 2000, 69 (09) :1867-1872